Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia

Journal of Psychopharmacology

Volumn 31, Issue 4, 2017, Pages 406-417

  Buonaguro, Elisabetta F ^a   Tomasetti, Carmine ^a   Chiodini, Paolo ^b   Marmo, Federica ^a   Latte, Gianmarco ^a   Rossi, Rodolfo ^a   Avvisati, Livia ^a   Iasevoli, Felice ^a   De Bartolomeis, Andrea ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antipsychotics; Arc; Homer1; N methyl D aspartate receptor; Treatment resistant schizophrenia

Indexed keywords

ARC PROTEIN; HALOPERIDOL; HOMER SCAFFOLDING PROTEIN; KETAMINE; MESSENGER RNA; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN HOMER 1A; PROTEIN HOMER 1B; PROTEIN HOMER 1C; REGULATOR PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; NERVE PROTEIN; NEUROLEPTIC AGENT; POSTSYNAPTIC DENSITY PROTEINS; SIGNAL PEPTIDE;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; GENE EXPRESSION; MALE; NONHUMAN; POSTSYNAPTIC DENSITY; POSTSYNAPTIC GLUTAMATERGIC TRANSMISSION; RAT; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PSYCHOSIS; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; DRUG RESISTANCE; GENE EXPRESSION; HALOPERIDOL; HOMER SCAFFOLDING PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KETAMINE; MALE; MEMBRANE PROTEINS; MINOCYCLINE; NERVE TISSUE PROTEINS; POST-SYNAPTIC DENSITY; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 85017412925     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881116658987     Document Type: Article

References (82)

1. Adembri C, Selmi V, Vitali L, et al. (2014) Minocycline but not tigecycline is neuroprotective and reduces the neuroinflammatory response induced by the superimposition of sepsis upon traumatic brain injury. Crit Care Med 42: e570-e582.
2. Ahuja N and Carroll BT (2007) Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 968-969.
3. Ambesi-Impiombato A, D'Urso G, Muscettola G, et al. (2003) Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Res Brain Res Protoc 11: 189-196.
4. Ambesi-Impiombato A, Panariello F, Dell'aversano C, et al. (2007) Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse 61: 429-439.
5. Amin AR, Attur MG, Thakker GD, et al. (1996) A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93: 14014-14019.
6. Beique JC, Na Y, Kuhl D, et al. (2011) Arc-dependent synapse-specific homeostatic plasticity. Proc Natl Acad Sci U S A 108: 816-821.
7. Bye N, Habgood MD, Callaway JK, et al. (2007) Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol 204: 220-233.
8. Chaudhry IB, Hallak J, Husain N, et al. (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26: 1185-1193.
9. Chaves C, de Marque CR, Wichert-Ana L, et al. (2010) Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 550-552.
10. Chaves C, Marque CR, Maia-de-Oliveira JP, et al. (2015) Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophr Res 161: 439-445.
11. Chen M, Ona VO, Li M, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
12. Chowdhury S, Shepherd JD, Okuno H, et al. (2006) Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron 52: 445-459.
13. de Bartolomeis A and Tomasetti C (2012) Calcium-dependent networks in dopamine-glutamate interaction: The role of postsynaptic scaffolding proteins. Mol Neurobiol 46: 275-296.
14. de Bartolomeis A, Avvisati L, Iasevoli F, et al. (2013a) Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment. Eur J Pharmacol 718: 502-523.
15. de Bartolomeis A, Marmo F, Buonaguro EF, et al. (2013b) Imaging brain gene expression profiles by antipsychotics: Region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. Eur Neuropsychopharmacol 23: 1516-1529.
16. de Bartolomeis A, Sarappa C, Buonaguro EF, et al. (2013c) Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog Neuropsychopharmacol Biol Psychiatry 46: 1-12.
17. de Bartolomeis A, Sarappa C, Magara S, et al. (2012) Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol 682: 1-11.
18. Deakin JF, Lees J, McKie S, et al. (2008) Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65: 154-164.
19. Drouin-Ouellet J, Brownell AL, Saint-Pierre M, et al. (2011) Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia 59: 188-199.
20. Du Y, Ma Z, Lin S, et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 14669-14674.
21. Gallo EF and Iadecola C (2011) Neuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase. J Neurosci 31: 6947-6955.
22. Gao C, Tronson NC and Radulovic J (2013) Modulation of behavior by scaffolding proteins of the post-synaptic density. Neurobiol Learn Mem 105: 3-12.
23. Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, et al. (2014) Minocycline as add-on treatment decreases the negative symptoms of schizophrenia: A randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov 8: 211-215.
24. Gonzalez JC, Egea J, Del Carmen Godino M, et al. (2007) Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. Eur J Neurosci 26: 2481-2495.
25. Hashimoto K, Tsukada H, Nishiyama S, et al. (2007) Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys. Biol Psychiatry 61: 577-581.
26. Hodkinson DJ, de Groote C, McKie S, et al. (2012) Differential effects of anaesthesia on the phMRI response to acute ketamine challenge. Br J Med Med Res 2: 373-385.
27. Hu JH, Park JM, Park S, et al. (2010) Homeostatic scaling requires group I mGluR activation mediated by Homer1a. Neuron 68: 1128-1142.
28. Iasevoli F, Buonaguro EF, Sarappa C, et al. (2014a) Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 54: 299-314.
29. Iasevoli F, Tomasetti C, Ambesi-Impiombato A, et al. (2009) Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action. Prog Neuropsychopharmacol Biol Psychiatry 33: 813-821.
30. Iasevoli F, Tomasetti C, Buonaguro EF, et al. (2014b) The glutamatergic aspects of schizophrenia molecular pathophysiology: Role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol 12: 219-238.
31. Iasevoli F, Tomasetti C and de Bartolomeis A (2013) Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: Relevance for neuropsychiatric diseases. Neurochem Res 38: 1-22.
32. Imbesi M, Uz T, Manev R, et al. (2008) Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett 447: 134-137.
33. Kelly DL, Sullivan KM, McEvoy JP, et al. (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 35: 374-381.
34. Kelly DL, Vyas G, Richardson CM, et al. (2011) Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 133: 257-258.
35. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al. (2014) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res 215: 540-546.
36. Kirov G, Pocklington AJ, Holmans P, et al. (2012) De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17: 142-153.
37. Klein NC and Cunha BA (1995) Tetracyclines. Med Clin North Am 79: 789-801.
38. Kriz J, Nguyen MD and Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268-278.
39. Krystal JH, Karper LP, Seibyl JP, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
40. Lees J, Hallak JE, Deakin JF, et al. (2004) Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 18: 337-339.
41. Levkovitz Y, Levi U, Braw Y, et al. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 1154: 154-162.
42. Levkovitz Y, Mendlovich S, Riwkes S, et al. (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71: 138-149.
43. Li Y, Popko J, Krogh KA, et al. (2013) Epileptiform stimulus increases Homer 1a expression to modulate synapse number and activity in hippocampal cultures. J Neurophysiol 109: 1494-1504.
44. Lipska BK and Weinberger DR (2000) To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 23: 223-239.
45. Liu F, Guo X, Wu R, et al. (2014) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial. Schizophr Res 153: 169-176.
46. Liu T, Jiang CY, Fujita T, et al. (2013) Enhancement by interleukin-1beta of AMPA and NMDA receptor-mediated currents in adult rat spinal superficial dorsal horn neurons. Mol Pain 9: 16.
47. Meffert MK, Premack BA and Schulman H (1994) Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release. Neuron 12: 1235-1244.
48. Miyaoka T, Yasukawa R, Yasuda H, et al. (2007) Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 304-307.
49. Mizoguchi H, Takuma K, Fukakusa A, et al. (2008) Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 196: 233-241.
50. Moghaddam B and Krystal JH (2012) Capturing the angel in 'angel dust': Twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38: 942-949.
51. Murphy BP, Chung YC, Park TW, et al. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res 88: 5-25.
52. Nam JH, Leem E, Jeon MT, et al. (2014) Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. Neuroreport 25: 489-495.
53. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118.
54. NIH (1996) NIH Guide for Care and Use of Laboratory Animals. NIH Publication No. 82-23. Washington, DC: National Academies Press.
55. Olney JW and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
56. Oya K, Kishi T and Iwata N (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 29: 483-491.
57. Papaleo F, Lipska BK and Weinberger DR (2012a) Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology 62: 1204-1220.
58. Papaleo F, Yang F, Garcia S, et al. (2012b) Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry 17: 85-98.
59. Paxinos G and Watson C (2007) The Rat Brain in Stereotaxic Coordinates. Sidney, Australia: Academic Press Inc.
60. Plane JM, Shen Y, Pleasure DE, et al. (2010) Prospects for minocycline neuroprotection. Arch Neurol 67: 1442-1448.
61. Pogun S, Dawson V and Kuhar MJ (1994) Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse 18: 21-26.
62. Polese D, de Serpis AA, Ambesi-Impiombato A, et al. (2002) Homer 1a gene expression modulation by antipsychotic drugs: Involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 27: 906-913.
63. Qurashi I, Collins J, Chaudhry I, et al. (2014) Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol 28: 707-708.
64. Robertson GS and Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46: 315-328.
65. Shepherd JD and Bear MF (2011) New views of Arc, a master regulator of synaptic plasticity. Nat Neurosci 14: 279-284.
66. Siddoway B, Hou H and Xia H (2014) Molecular mechanisms of homeostatic synaptic downscaling. Neuropharmacology 78: 38-44.
67. Tan HY, Callicott JH and Weinberger DR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17: i171-i181.
68. Tikka T, Fiebich BL, Goldsteins G, et al. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21: 2580-2588.
69. Tomasetti C, Dell'Aversano C, Iasevoli F, et al. (2007) Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: Implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience 150: 144-158.
70. Tomasetti C, Dell'Aversano C, Iasevoli F, et al. (2011) The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry 35: 184-197.
71. Trotti D, Rossi D, Gjesdal O, et al. (1996) Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem 271: 5976-5979.
72. Tuominen HJ, Tiihonen J and Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 72: 225-234.
73. Wang JQ, Arora A, Yang L, et al. (2005) Phosphorylation of AMPA receptors: Mechanisms and synaptic plasticity. Mol Neurobiol 32: 237-249.
74. Wang X, Zhu S, Drozda M, et al. (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100: 10483-10487.
75. Wiedholz LM, Owens WA, Horton RE, et al. (2008) Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 13: 631-640.
76. Woolley ML, Waters KA, Gartlon JE, et al. (2009) Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl) 202: 343-354.
77. Wu DC, Jackson-Lewis V, Vila M, et al. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
78. Yrjanheikki J, Keinanen R, Pellikka M, et al. (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95: 15769-15774.
79. Yrjanheikki J, Tikka T, Keinanen R, et al. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96: 13496-13500.
80. Zhang L, Kitaichi K, Fujimoto Y, et al. (2006a) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 30: 1381-1393.
81. Zhang L, Shirayama Y, Shimizu E, et al. (2006b) Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544: 1-9.
82. Zhu S, Stavrovskaya IG, Drozda M, et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.